Neonatal Herpetic Infection

Abstract

ALTHOUGH the prognosis in herpes simplex encephalitis remains unclear in view of problems inherent in providing laboratory confirmation of diagnoses,1 reports in current literature 2-8 indicate the disease is severe, often fatal, frequently leaving survivors with neurological sequelae. Until recently, treatment consisted largely of supportive care, with occasional administration of \g=g\-globulin or hyperimmune plasma. During the past three years, several authors described beneficial results in herpes simplex encephalitis with systemic use of idoxuridine (5-iodo-2\m='\-deoxyuridine) .8-13 However, no one has reported experience with systemic use of idoxuridine in the premature infant. Partridge and Millis 14 used intravenously administered idoxuridine in a combined, five-day course of intermittent and continuous infusion in a newborn term infant with systemic herpes simplex. The infant received a total dose of 580 mg/kg and showed clinical improvement, with no toxicity noted. The infant died